Loading
A phase 2 trial of Whole-body MRI in Prostate cancer, run by The European Uro-Oncology Group, completed.
PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide is a phase 2 interventional study registered as NCT02814968 by The European Uro-Oncology Group, with 66 participants recorded, started 2015-02 and reaching its primary completion in 2020-06. Interventions recorded: Enzalutamide, 18-FDG PET/CT, Whole body MRI, Bone scan. Conditions recorded: Prostate Cancer Metastatic.
Linked to the technology Whole-body MRI because the registry names it ("whole body mri") among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Whole-body MRI, Enzalutamide, Prostate cancer and the tag pipeline.
Shares Whole-body MRI, Prostate cancer and the tag pipeline.
Shares Enzalutamide, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/